Welcome to the Antimicrobial Chemotherapy Virtual Conference 2023

Download programme

This virtual conference was jointly organised by BSAC and GARDP.  For ACC2023, the collaborating organisations were Africa CDC and ReAct Africa.  

 

Programme

Select to see different time zones. Default is GMT.

SESSION ONE: KEYNOTE PRESENTATION
Chair: Professor Laura JV Piddock, Scientific Director, GARDP - View Bio
1000
1100
1200
1100
View session one. This video consists of the following presentations:
1030
1130
1230
1130
Introductory remarks
Professor Laura JV Piddock, Scientific Director, GARDP - View Bio
1035
1135
1235
1135
Is antimicrobial discovery responding to current needs? How do we move from here?
Dr Mirfin Mpundu, Director, ReAct Africa - View Bio
1055
1155
1255
1155
Q&A

SESSION TWO: Drug discovery - new targets and new chemistry
Chair: Dr Keith Miller, Senior Lecturer in Medical Microbiology, Sheffield Hallam University - View Bio
1000
1100
1200
1100
View session two. This video consists of the following presentations:
1115
1215
1315
1215
Antiviral drug discovery: preparing for the next pandemic
Professor Rosemary Dorrington, Professor: Marine natural Products Research, Rhodes University - View Bio
1130
1230
1330
1230
Awakening sleeping antibiotics
Professor Gilles P. van Wezel, Director, Institute of Biology & Professor of Microbial Biotechnology, Leiden University, The Netherlands - View Bio
1145
1245
1345
1245
Bioinformatics as a tool to identify and synthesise of new antibiotics
Dr César de la Fuente, Presidential Assistant Professor, University of Pennsylvania - View Bio
1200
1300
1400
1300
Q&A

SESSION THREE: Preclinical antimicrobial development
Chair: Dr Christopher Longshaw, Senior Director, EU Scientific Affairs, Shionogi BV & BSAC Honorary Treasurer - View Bio
1220
1320
1420
1320
View session three. This video consists of the following presentations:
1220
1320
1420
1320
Recent developments in PK-PD
Professor Lena Friberg, Professor of Pharmacokinetics and Pharmacodynamics at the Department of Pharmacy, Uppsala University, Sweden - View Bio
1235
1335
1435
1335
Challenges of discovery of new antibiotics
Dr Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna - View Bio
1250
1350
1450
1350
Discovery and pre-clinical development of new antimicrobials in Africa
Dr Greg Basarab, H3D - University of Cape Town - View Bio
1305
1405
1505
1405
Q&A

SESSION FOUR: Panel discussion - Development of non-traditional antimicrobials
Chair: Dr Ursula Theuretzbacher, Center for Anti-Infective Agents, Vienna - View Bio
1325
1425
1525
1425
View session four. This video consists of the following presentations:
1325
1425
1525
1425
Panellists:
Dr Peter Jackson, Executive Director, INFEX Therapeutics Ltd - View Bio
Dr Richard Alm, Chief Scientist, CARB-X - View Bio
Dr Nagasuma Chandra, PhD Professor Department of Biochemistry Indian Institute of Science, Bangalore, India - View Bio
1420
1520
1620
1520
Q&A
1430
1530
1630
1530
Day One - Closing remarks
Dr Christopher Longshaw, Senior Director, EU Scientific Affairs, Shionogi BV & BSAC Honorary Treasurer - View Bio
SESSION FIVE: Clinical Development and Use of New agents
Chair: Alison Luckey, GARDP - View Bio
1030
1130
1230
1130
View session five. This video consists of the following presentations:
1030
1130
1230
1130
Introductory remarks
Dr Christopher Longshaw, Senior Director, EU Scientific Affairs, Shionogi BV & BSAC Honorary Treasurer - View Bio
1035
1135
1235
1135
Zoliflodacin Phase 3 study
Professor Sinead Delany-Moretlwe, Director: Research, Wits RHI & Professor of Global Health & Infectious Diseases, University of the Witwatersrand, Johannesburg - View Bio
1050
1150
1250
1150
Clinical trials in countries with a high burden of drug resistance
Dr Ashima Bhatia, MD – Chief Clinical Officer & Head, Global Clinical Development, Wockhardt - View Bio
Dr Manish Shah, VP, Global Clinical Development, Wockhardt - View Bio
1105
1205
1305
1205
Compassionate use of Cefiderocol to treat documented XDR-AB infections at the intensive care unit
Professor Federico Pea, Full Professor of Pharmacology, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Italy - View Bio
1120
1220
1320
1220
Q&A

SESSION SIX: ORAL POSTER PRESENTATIONS
Chair: Dr Mirfin Mpundu, Director, ReAct Africa - View Bio
1140
1240
1340
1240
View session six. This video consists of the following presentations:
1140
1240
1340
1240
Association of meropenem with ethambutol enhances the exposure of Mycobacterium tuberculosis peptidoglycan and promotes its synergistic killing
Mr Francisco Olivença, PhD Candidate, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal
1145
1245
1345
1245
Assessment of availability of essential antimicrobial agents in north India
Dr Rachna Rohilla, Assistant Professor, Department of Pharmacology, AIIMS Bathinda
1150
1250
1350
1250
The SA-UK Antimicrobial Drug Discovery Hub: Harnessing the potential of natural products as antimicrobial lead compounds
Miss Roxanne Leigh Higgitt, Department of Biochemistry and Microbiology, Rhodes University, Makhanda, South Africa
1155
1255
1355
1255
Interplay Between Clinical Stringent Response-Activating Mutations, Antibiotic Tolerance and Bacterial Fitness
Dr Joanne Hobbs, Research Associate & Adjunct Assistant Professor, Department of Biochemistry & Microbiology, University of Victoria, Canada
1200
1300
1400
1300
Infection control of Healthcare-associated infections in Ukraine
Dr Yulian Konechnyi, National Medical University, Lviv, Ukraine
1205
1305
1405
1305
Q&A

SESSION SEVEN: National action plan progress/policy
Chair: Dr Yewande Alimi, Antimicrobial Resistance (AMR) Program Coordinator, Africa Centres for Disease Control and Prevention & co-lead for the Africa Union Task force on AMR - View Bio
1225
1325
1425
1325
View session seven. This video consists of the following presentations:
1225
1325
1425
1325
Development of the National Policy and Action Plan and accompanying strategies for Antimicrobial Resistance in Kenya
Dr Evelyn Wesangula, Senior AMR Control Specialist, East Central and Southern Africa Health Community (ECSA- HC) - View Bio
1240
1340
1440
1340
MAAP DATA
Dr Pascale Ondoa, Director of Science & New Initiatives, African Society for Laboratory Medicine (ASLM) - View Bio
1255
1355
1455
1355
Widening access to antibiotics in LMICs
Professor Samuel Kariuki, Chief Research Scientist and Director, Research and Development, Kenya Medical Research Institute (KEMRI), Kenya - View Bio
1310
1410
1510
1410
Q&A

SESSION EIGHT: Panel discussion - Regulatory paths for new treatment modalities
Chair: Dr Valeria Gigante, Team Lead, One Health Research Priority-setting and Synergy in AMR, WHO - View Bio
1330
1430
1530
1430
View session eight. This video consists of the following presentations:
1330
1430
1530
1430
Panellists:
Dr Markus Zeitlinger, University of Vienna - View Bio
Dr Mimi Yen, Phage Pro - View Bio
Dr Joe Campbell, National Institute of Allergies and Infectious Diseases (NIAID) - View Bio
1420
1520
1620
1520
Q&A
1430
1530
1630
1530
Closing remarks
Professor Laura JV Piddock, Scientific Director, GARDP - View Bio

Virtual poster gallery

Click here to view the virtual poster gallery from the conference

Top